HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lawrence E Flaherty Selected Research

Melanoma (Melanoma, Malignant)

1/2021Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
1/2020Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
1/2018A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
11/2017High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
3/2017Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
2/2015Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
11/2014Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
11/2014New options for the adjuvant treatment of cutaneous melanoma?
10/2014Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.
2/2012Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lawrence E Flaherty Research Topics

Disease

20Melanoma (Melanoma, Malignant)
01/2021 - 02/2002
7Neoplasms (Cancer)
01/2015 - 02/2002
3Nausea
02/2015 - 11/2007
3Neoplasm Metastasis (Metastasis)
02/2012 - 01/2005
2Brain Neoplasms (Brain Tumor)
11/2017 - 01/2010
2Breast Neoplasms (Breast Cancer)
01/2015 - 11/2011
2Renal Cell Carcinoma (Grawitz Tumor)
02/2007 - 01/2005
1Exanthema (Rash)
01/2021
1Anemia
02/2015
1Fatigue
02/2015
1Leukemia
11/2014
1Diarrhea
10/2010
1Neuroendocrine Carcinoma
10/2010
1Merkel Cell Carcinoma
10/2010
1Dehydration (Water Stress)
11/2007
1Kidney Neoplasms (Kidney Cancer)
02/2007

Drug/Important Bio-Agent (IBA)

8InterferonsIBA
01/2021 - 01/2005
5Interleukin-2 (IL2)IBA
01/2018 - 01/2005
4Interferon alpha-2 (Roferon-A)FDA Link
01/2020 - 01/2005
4Dacarbazine (DIC)FDA LinkGeneric
11/2014 - 12/2008
4Thalidomide (Thalomid)FDA Link
01/2010 - 02/2007
3IpilimumabIBA
01/2021 - 07/2011
3VaccinesIBA
10/2014 - 04/2002
2VemurafenibIBA
01/2018 - 07/2011
2Vinblastine (Vinblastine Sulfate)FDA Link
11/2014 - 12/2008
2Cisplatin (Platino)FDA LinkGeneric
11/2014 - 12/2008
2HLA-A2 Antigen (HLA A2 Antigen)IBA
10/2014 - 04/2002
2Histocompatibility Antigens Class IIBA
10/2014 - 04/2002
2MelacineIBA
10/2014 - 04/2002
2Cancer VaccinesIBA
04/2002 - 04/2002
1Immunosuppressive Agents (Immunosuppressants)IBA
01/2021
12,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA
02/2015
1Amyloid Precursor Protein Secretases (beta-Secretase)IBA
02/2015
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2015
1taxaneIBA
01/2015
1AnthracyclinesIBA
01/2015
1human ERBB2 proteinIBA
01/2015
1Paclitaxel (Taxol)FDA LinkGeneric
01/2015
1Doxorubicin (Adriamycin)FDA LinkGeneric
01/2015
1Hormones (Hormone)IBA
01/2015
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
11/2014
1AntigensIBA
10/2014
1HLA-C*03 antigenIBA
10/2014
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
02/2012
1Sorafenib (BAY 43-9006)FDA Link
02/2012
1Drug CombinationsIBA
02/2012
1tipifarnib (R115777)IBA
02/2012
1temsirolimusFDA Link
02/2012
1Mitogen-Activated Protein KinasesIBA
02/2012
1Docetaxel (Taxotere)FDA Link
11/2011
1Trastuzumab (Herceptin)FDA Link
11/2011
1Filgrastim (Neupogen)FDA Link
11/2011
1Vinorelbine (Navelbine)FDA LinkGeneric
11/2011
1Imatinib Mesylate (Gleevec)FDA Link
10/2010
1Temozolomide (Temodar)FDA LinkGeneric
01/2010
1peginterferon alfa-2b (Pegintron)FDA Link
07/2008
1CytokinesIBA
01/2005
1HLA-B44 AntigenIBA
04/2002
1Peptides (Polypeptides)IBA
04/2002
1P-2 (P 2)IBA
04/2002
1HLA-B45 antigenIBA
04/2002
1HLA-A28 antigenIBA
04/2002
1pyrazine-2-diazohydroxide (diazohydroxide)IBA
02/2002
1DNA (Deoxyribonucleic Acid)IBA
02/2002
1PyrazinesIBA
02/2002

Therapy/Procedure

11Therapeutics
01/2020 - 04/2002
6Drug Therapy (Chemotherapy)
02/2015 - 02/2002
4Immunotherapy
10/2014 - 04/2002
2Biological Therapy
11/2014 - 10/2002